Terlipressin is a synthetic analogue of vasopressin used as a vasoactive drug in the management of hypotension. It is a prodrug, which is converted to (Lys8)- vasopressin after removal of the N-terminal triglycine in vivo. Terlipressin has a longer duration of action and a better safety profile than the parent compound.